Software we have built
The 4 programmes whose artefact is software. Each one is a research artefact at the stage it has actually reached, and each links to the full case study behind it.
None of this is a product. Nothing listed here is CE marked, none of it has been through a conformity assessment, and none of it is in use in patient care. Where a build turned out to sit inside EU MDR Annex VIII Rule 11, we say so on its page and we stopped there rather than deploying behind a disclaimer.
Which subgroups carry which cancer risk
Genotype, lifestyle and socioeconomic data read together at population level. One of the algorithms delivered under CODIGE. Population associations, never an individual risk score.
Status. Research use. Population-level analysis. Not a medical device, and it produces no output about any individual.
What it does not do. No individual risk score. No screening. No eligibility. No output that resolves to one person.
Read the case study →An agent that prepares the evidence for a tumour board
A clinician enters a case, the agent searches published AIOM and ESMO guidance and returns one page the panel can read in the room. Built with an Italian local health authority. The pilot is waiting on regional approval and the agent is not in use in care.
Status. Research use. Not in use in care. Treated as within the scope of EU MDR Annex VIII Rule 11, not CE marked, and no conformity assessment has been carried out.
What it does not do. It is not in use and it has never informed a clinical decision.
Read the case study →An agent for the gap between rheumatology visits
Months pass between outpatient visits, and every visit begins from a reconstruction by memory. What is worth capturing in between, and does capturing it change the next one.
Status. Design stage. Nothing is deployed. No symptom threshold, alert or flag, which is a design decision rather than an omission.
What it does not do. Nothing yet, and specifically: no symptom threshold, no alert, no flag.
Read the case study →A compass for hospital medicines spending
A hospital already holds every figure it needs to see where value is leaking. It is not organised in a way that points anywhere. This reads the flows an authority already produces and points at the molecule, the channel and the ward where the money is going.
Status. Research use. Management analytics. No patient-level output, no prescribing access, and no recommendation about any medicine for any patient.
What it does not do. It has no access to prescribing systems and produces no patient-level output. The minimum unit of aggregation is the dispensing structure.
Read the case study →